Compare USIO & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USIO | GOSS |
|---|---|---|
| Founded | 1998 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 65.6M |
| IPO Year | 1999 | 2018 |
| Metric | USIO | GOSS |
|---|---|---|
| Price | $2.35 | $10.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $4.00 | ★ $4.19 |
| AVG Volume (30 Days) | 282.4K | ★ 4.7M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $28,200,535.00 | ★ $48,471,000.00 |
| Revenue This Year | $12.15 | N/A |
| Revenue Next Year | $8.57 | $201.64 |
| P/E Ratio | $228.00 | ★ N/A |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.03 | $0.11 |
| 52 Week High | $3.06 | $12.52 |
| Indicator | USIO | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 79.61 |
| Support Level | $2.15 | $0.18 |
| Resistance Level | $2.61 | $12.52 |
| Average True Range (ATR) | 0.16 | 0.98 |
| MACD | -0.03 | 0.37 |
| Stochastic Oscillator | 25.90 | 86.51 |
Usio Inc is a cloud-based Fintech payment processor. The company serves multiple industry verticals with technology that facilitates payment acceptance and funds disbursement in a single, full-stack ecosystem. It provides payment acceptance through multiple payment methods, including payment facilitation, prepaid card, and electronic billing products and services to businesses, merchants, and consumers. The company's reportable operating segments are Output Solutions and Merchant Services, and these segments.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).